Acelyrin.Virtual Investor Event on Phase 2 Data, Phase 3 Design for Thyroid Eye Disease

 ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a virtual investor event on Monday, January 6, 2025 at 4:30 PM ET to provide updated Phase 2 data for subcutaneous lonigutamab further supporting its potential for a best-in-class efficacy and safety profile in Thyroid Eye Disease (TED). The event will also feature external clinician perspectives on the continuing unmet needs in TED and disclose the design for the Phase 3 LONGITUDE program, which was developed following a successful End-of-Phase 2 meeting with the FDA to be the most inclusive registrational program to date in TED. To register, click here.

 A live question and answer session will follow the formal presentations and a recording of the webcast will be available and archived on the Company’s website for approximately 30 days.

https://www.globenewswire.com/news-release/2025/01/03/3003799/0/en/ACELYRIN-INC-to-Host-Virtual-Investor-Event-to-Share-new-Phase-2-Data-and-Phase-3-Program-Design-for-Subcutaneous-Lonigutamab.html